F. RAMACCIOTTI, D. STAINER, G. MORESSA, G. SCHIAVON - Vol. 9, March 2003, Issue 1
Testo Immagini Bibliografia Summary Indice
Antipsicotici tradizionali e olanzapina: studio
retrospettivo su trattamento farmacologico
e prestazioni riabilitative erogate al paziente psicotico
Traditional antipsychotics and olanzapine: retrospective study on drug
treatment
and rehabilitation provided to psychotic patients
1 Altamura AC, Velona I, Curreli R, Bravi D. Olanzapine in the treatment of paranoid schizophrenia. Eur Neuropsychopharmacol 1999;9(Suppl 5):S297.
2 Awad AG, Hogan TP, Voruganti LNP, Heslegrave RJH. Patient’s subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl 3):123-32.
3 Balestrieri M, Bellantuono C, Vampini C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol 2000;15:499-512.
4 Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
5 Beasley CM Jr, Sanger T, Satterlee W, Tollefson GD, Tran PV, Hamilton S. Olanzapine versus placebo: results of a double-blind fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-67.
6 Beasley CM, Tollefson DG, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58(Suppl 10):7-12.
7 Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(Suppl 10):13-7.
8 Bellantuono C, Vampini C, Balestrieri M. Psicofarmacoterapia della schizofrenia e delle sindromi deliranti. In: Bellantuono C, Balestrieri M, eds. Gli psicofarmaci. Farmacologia e terapia. Roma: Il Pensiero Scientifico Editore 1997.
9 Bellantuono C, Vampini C, Balestrieri M. I nuovi antipsicotici. Efficacia, tollerabilità e modalità d’uso nella pratica clinica. Roma: Il Pensiero Scientifico Editore 2001.
1 0 Boyer P, Lecubrier Y, Puech J, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72.
1 1 Breyer A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with tratment - resistant schizophrenia. Biol Psychiatry 1999;45:403-11.
1 2 Casey DE. Side effects profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(Suppl 11):40-5.
1 3 Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment – resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
1 4 Geddes J, Freementle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000;321:1371-6.
1 5 Goldberg TE, Weinberger DR. Effects of neuroleptic medications on the cognition of patient with schizophrenia: a review of recent studies. J Clin Psychiatry 1996;57(Suppl 9):62-5.
1 6 Gomez CG, Sacristan JA, Hernandez J, Breier A, Carasco R, Saiz CA, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia. J Clin Psychiatry. 2000;61:335-43.
1 7 Harvey PD, Keefe RS. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums 1997;2:41-55.
1 8 J Clin Psychiatry 59(Suppl 3):21-5.
1 9 Kapur S, Remington G. Atypical antipsychotics. Br Med J 2000;321:1360-1.
2 0 Keck PE, McElroy SL, Stakowski SM. New developments in the pharmachological treatment of schizo-affective disorder. J Clin Psychiatry 1996;57(Suppl 9):41-8.
2 1 Marder SR. Facilitating compliance with antipsychotic medications. J Clin Psychiatry 1998;59(Suppl 3):21-5.
2 2 Meltzer HY. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998;59(Suppl 12):3-9.
2 3 Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objectives psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl 3):133-8.
2 4 Purdon SE, Jones BD, Labelle A, Addington D, David SR, Breier A, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-58.
2 5 Stahl SM. La psicofarmacologia degli antipsicotici. Londra: Martin Dunitz 2000.
2 6 Taylor D, Drumond S, Pendlebury J. Olanzapine in practice. Psychiatr Bull 1998;22:552-4.
2 7 Tollefson DG, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo – and haloperidol – controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.